News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,519 Results
Type
Article (39382)
Company Profile (247)
Press Release (652890)
Section
Business (204026)
Career Advice (2005)
Deals (35404)
Drug Delivery (93)
Drug Development (80943)
Employer Resources (169)
FDA (16133)
Job Trends (14828)
News (344876)
Policy (32473)
Tag
Academia (2535)
Alliances (49313)
Alzheimer's disease (1314)
Approvals (16117)
Artificial intelligence (199)
Bankruptcy (357)
Best Places to Work (11637)
Biotechnology (175)
Breast cancer (225)
Cancer (1710)
Cardiovascular disease (128)
Career advice (1669)
CAR-T (121)
Cell therapy (353)
Clinical research (65242)
Collaboration (659)
Compensation (370)
COVID-19 (2564)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6282)
Earnings (85435)
Employer resources (146)
Events (110855)
Executive appointments (564)
FDA (17032)
Funding (602)
Gene therapy (245)
GLP-1 (648)
Government (4357)
Healthcare (18765)
Infectious disease (2675)
Interviews (310)
IPO (16460)
Job creations (3627)
Job search strategy (1420)
Layoffs (437)
Legal (7885)
Lung cancer (255)
Manufacturing (235)
Medical device (13261)
Medtech (13266)
Mergers & acquisitions (19319)
Metabolic disorders (548)
Neuroscience (1715)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (306)
Opinion (193)
Patents (162)
People (56828)
Phase I (20314)
Phase II (28744)
Phase III (21397)
Pipeline (711)
Postmarket research (2562)
Preclinical (8575)
Radiopharmaceuticals (241)
Rare diseases (321)
Real estate (5897)
Regulatory (21917)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1791)
Startups (3567)
United States (18427)
Vaccines (612)
Weight loss (208)
Date
Today (97)
Last 7 days (605)
Last 30 days (2610)
Last 365 days (34479)
2025 (4416)
2024 (35217)
2023 (40076)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (716)
Arizona (211)
Asia (37506)
Australia (6132)
California (4761)
Canada (1715)
China (392)
Colorado (217)
Connecticut (230)
Europe (80383)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (738)
Massachusetts (3599)
Michigan (198)
Minnesota (334)
New Jersey (1346)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1096)
South America (1093)
Southern California (1791)
Texas (701)
Utah (141)
Washington State (467)
692,519 Results for "ocugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
February 12, 2025
·
7 min read
Press Releases
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
January 16, 2025
·
5 min read
Press Releases
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
January 27, 2025
·
6 min read
Press Releases
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
January 13, 2025
·
6 min read
Business
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Ocugen, Inc. announced the appointment of Dr. Huma Qamar as Chief Medical Officer.
March 18, 2024
·
3 min read
Pharm Country
Ocugen to Present at May 2024 Investor Conferences
Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder, Ocugen, will present at The Citizens JMP Life Sciences Conference taking place at the New York Hilton Midtown from May 13 – 14, 2024.
May 10, 2024
·
3 min read
Pharm Country
Ocugen to Present at BIO International Convention 2024
Ocugen, Inc. today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
May 29, 2024
·
4 min read
Drug Development
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.
June 20, 2024
·
7 min read
Press Releases
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 12, 2024
·
2 min read
Pharm Country
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Ocugen, Inc. today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL.
May 2, 2024
·
5 min read
1 of 69,252
Next
